Efficacy and safety of intravenous pamidronate infusion for treating osteoporosis in children and adolescents
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment. This study was performed to investigate the effect of pamidronate infusion on osteoporosis in children and adolescents. Methods: This study included 13 unrelated pediatric patients (10 males and 3 females) whose bone mineral density (BMD) z-score was <-2.0. Pamidronate was administered intravenously at a dosage of 1 mg/kg for 3 consecutive days every 4 months. Clinical and biochemical findings were reviewed retrospectively. The BMD values of the lumbar spine and femoral neck were assessed by dual energy x-ray absorptiometry at baseline and annually. Results: The underlying diseases were immobilization (62%), inflammatory bowel disease (23%), protein-losing enteropathy (8%), and idiopathic juvenile osteoporosis (8%). The mean age at the start of treatment was 12.7±4.3 years. Duration of treatment ranged from 12–50 months. The baseline height-standard deviation score (SDS) and weight-SDS were -2.01±2.08 and -2.60±1.62, respectively. The lumbar spine BMD z-scores improved significantly after 1 year of pamidronate treatment, but the femoral neck BMD z-scores did not. However, both z-scores had significantly increased by the end of treatment. Conclusion: This study demonstrated that pamidronate treatment increased BMD in pediatric patients with osteoporosis with no significant adverse events. Further studies are required to better define the long-term efficacy and safety of pamidronate therapy in a large number of pediatric patients.
Abstract
Purpose: Osteoporosis is a skeletal disorder characterized by reduced bone mass that results in increased risk of fractures. Pediatric osteoporosis can be caused by monogenic diseases, chronic diseases, and/or their treatment. This study was performed to investigate the effect of pamidronate infusion on osteoporosis in children and adolescents. Methods: This study included 13 unrelated pediatric patients (10 males and 3 females) whose bone mineral density (BMD) z-score was <-2.0. Pamidronate was administered intravenously at a dosage of 1 mg/kg for 3 consecutive days every 4 months. Clinical and biochemical findings were reviewed retrospectively. The BMD values of the lumbar spine and femoral neck were assessed by dual energy x-ray absorptiometry at baseline and annually. Results: The underlying diseases were immobilization (62%), inflammatory bowel disease (23%), protein-losing enteropathy (8%), and idiopathic juvenile osteoporosis (8%). The mean age at the start of treatment was 12.7±4.3 years. Duration of treatment ranged from 12–50 months. The baseline height-standard deviation score (SDS) and weight-SDS were -2.01±2.08 and -2.60±1.62, respectively. The lumbar spine BMD z-scores improved significantly after 1 year of pamidronate treatment, but the femoral neck BMD z-scores did not. However, both z-scores had significantly increased by the end of treatment. Conclusion: This study demonstrated that pamidronate treatment increased BMD in pediatric patients with osteoporosis with no significant adverse events. Further studies are required to better define the long-term efficacy and safety of pamidronate therapy in a large number of pediatric patients.
참고문헌 (29)
- Marrani E, "Pediatric osteoporosis : diagnosis and treatment considerations", Drugs, 77, pp.679~695 (2017)
- Shuhart CR, "Executive summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics", J Clin Densitom, 22, pp.453~471 (2019)
- Arundel P, "Primary osteoporosis", Endocr Dev, 28, pp.162~175 (2015)
- Ward LM, "The management of osteoporosis in children", Osteoporos Int, 27, pp.2147~2179 (2016)
- Bianchi ML, "Osteoporosis in children and adolescents", Bone, 41, pp.486~495 (2007)
- Russell RG, "Bisphosphonates : mode of action and pharmacology", Pediatrics, 119(Suppl 2), pp.S150~S162 (2007)
- Eghbali-Fatourechi G, "Bisphosphonate therapy in pediatric patients", J Diabetes Metab Disord, 13, pp.109~ (2014)
- Glorieux FH, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta", N Engl J Med, 339, pp.947~952 (1998)
- Henderson RC, "Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy : a randomized, placebo-controlled clinical trial", J Pediatr, 141, pp.644~651 (2002)
- Acott PD, "Pamidronate treatment of pediatric fracture patients on chronic steroid therapy", Pediatr Nephrol, 20, pp.368~373 (2005)
- 최진호, "Short-term Efficacy of Monthly Pamidronate Infusion in Patients with Osteogenesis Imperfecta", Journal of Korean Medical Science, 22(2), pp.209~212 (2007), 대한의학회
- Se Won Lim, "Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density", Annals of Pediatric Endocrinology & Metabolism, 21(1), pp.21~25 (2016), 대한소아내분비학회
- Rauch F, "Risedronate in the treatment of mild pediatric osteogenesis imperfecta : a randomized placebo-controlled study", J Bone Miner Res, 24, pp.1282~1289 (2009)
- Ooi HL, "Zoledronic acid improves bone mineral density in pediatric spinal cord injury", J Bone Miner Res, 27, pp.1536~1540 (2012)
- 김재현, "The 2017 Korean National Growth Charts for children and adolescents: development, improvement, and prospects", Clinical and Experimental Pediatrics, 61(5), pp.135~149 (2018), 대한소아청소년과학회
- Lim JS, "Bone mineral density according to age, bone age, and pubertal stages in korean children and adolescents", J Clin Densitom, 13, pp.68~76 (2010)
- Kang MJ, "Body composition and bone density reference data for Korean children, adolescents, and young adults according to age and sex : results of the 2009-2010 Korean National Health and Nutrition Examination Survey(KNHANES)", J Bone Miner Metab, 34, pp.429~439 (2016)
- Fan B, "Does standardized BMD still remove differences between Hologic and GE-Lunar state-of-the-art DXA systems", Osteoporos Int, 21, pp.1227~1236 (2010)
- Dwan K, "Bisphosphonate therapy for osteogenesis imperfecta", Cochrane Database Syst Rev, 10, pp.CD005088~ (2014)
- Saraff V, "Endocrinology and adolescence : osteoporosis in children : diagnosis and management", Eur J Endocrinol, 173, pp.R185~R197 (2015)
- Jung KJ, "Association of gross motor function classification system level and school attendance with bone mineral density in patients with cerebral palsy", J Clin Densitom, 21, pp.501~506 (2018)
- Grissom LE, "Bone densitometry in pediatric patients treated with pamidronate", Pediatr Radiol, 35, pp.511~517 (2005)
- Baroncelli GI, "Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis : comparison with untreated patients", J Bone Miner Metab, 31, pp.533~543 (2013)
- Ward L, "Bisphosphonate therapy for children and adolescents with secondary osteoporosis", Cochrane Database Syst Rev, (4), pp.CD005324~ (2007)
- Plotkin H, "Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy : a pilot study", Dev Med Child Neurol, 48, pp.709~712 (2006)
- Lee YA, "Pamidronate therapy in children and adolescents with osteoporosis", Horm Res, 70, pp.27~ (2008)
- 문순정, "The effect of low-dose intravenous bisphosphonate treatment on osteoporosis in children with quadriplegic cerebral palsy", Clinical and Experimental Pediatrics, 60(12), pp.403~407 (2017), 대한소아청소년과학회
- Rauch F, "Osteogenesis imperfecta", Lancet, 363, pp.1377~1385 (2004)
- Swaminathan R, "Biochemical markers of bone turnover", Clin Chim Acta, 313, pp.95~105 (2001)